Company intelligence / Profile preview

Sunho Chemical

Nanjing, Jiangsu, Chinatw.linkedin.com ↗

Ownership: Private
Development stage: Other

Overview

Six clinical-stage programs in oncology and autoimmune disease; several preclinical assets in inflammation/metabolic disease. Lead assets include fully fucose-deficient HER2 mAb and multiple immunocytokines targeting PD1/IL15, EGFR/IL10, B7H3/IL10 as well as a bispecific CD24/4‑1BB antibody. Seeking licensing partners globally. No published pivotal or late-stage results yet.[5][8]

Therapeutic areas: OncologyMetabolic DisordersImmunology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyImmunocytokine (Biologic)
Industry: Biotech

Beyond the preview

Go deeper on Sunho Chemical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sunho Chemical.

Explore the full profile